Skip to main content

Travel Vaccination

  • Chapter
  • First Online:
Adult Vaccinations

Part of the book series: Practical Issues in Geriatrics ((PIG))

  • 716 Accesses

Abstract

The World Tourism Organization estimated the number of international tourist arrivals to be 1.2 billion in 2016, an increase of 46 million over the previous year, a figure that has been rising constantly for 7 consecutive years. In this context, a long list of vaccines are dispensed and administered in travel clinics around the world. There are two main steps in immunizing travelers, namely, to update routine vaccinations and, second, to provide travel-specific immunization. For the first step, knowledge of a patient’s previous immunizations and personal medical history is necessary. For the second step, considerably more issues must be covered, including obtaining information about the patient’s projected itinerary, mode of travel, planned living conditions during the stay, and purpose of travel. This review focuses on three major and common travel vaccines, namely, yellow fever, dengue, and rabies. It should be remembered that vaccines exist both to protect the visited populations and the travelers, plus those the travelers come in contact with on their return from endemic areas. Travel should be used as a good opportunity to update routine vaccines.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. World Tourism Organization (UNWTO). UNWTO Annual Report 2016. UNWTO, Madrid, Spain. 2017. https://www.e-unwto.org/doi/pdf/10.18111/9789284418725. Accessed 29 June 2018.

  2. Douam F, Ploss A. Yellow fever virus: knowledge gaps impeding the fight against an old foe. Trends Microbiol. 2018;26(11):913–28.

    Article  CAS  Google Scholar 

  3. World Health Organization. WHO global yellow fever data base. http://apps.who.int/globalatlas/default.asp. Accessed 30 June 2018. (Latest data for Yellow Fever from 2005).

  4. World Health Organization. International Health Regulations. 3rd ed. 2005. http://www.who.int/ihr/publications/9789241580496/en/. Accessed 30 June 2018.

  5. Meeting of the Strategic Advisory Group of Experts on immunization, April 2013—conclusions and recommendations. Wkly Epidemiol Rec. 2013;88(20):201–6.

    Google Scholar 

  6. Vaccines and vaccination against yellow fever. WHO position paper—June 2013. Wkly Epidemiol Rec. 2013;88(27):269–83.

    Google Scholar 

  7. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP): summary report, February 26, 2015. Atlanta, GA: US Department of Health and Human Services, CDC; 2015. http://www.cdc.gov/vaccines/acip/meetings/meetings-info.html. Accessed 30 June 2018.

  8. Staples JE, Bocchini JA Jr, Rubin L, Fischer M, Centers for Disease C, Prevention. Yellow fever vaccine booster doses: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(23):647–50.

    PubMed  PubMed Central  Google Scholar 

  9. Niedrig M, Lademann M, Emmerich P, Lafrenz M. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Tropical Med Int Health. 1999;4(12):867–71.

    Article  CAS  Google Scholar 

  10. Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, Marano N, et al. Adverse event reports following yellow fever vaccination. Vaccine. 2008;26(48):6077–82.

    Article  CAS  Google Scholar 

  11. Ahuka-Mundeke S, Casey RM, Harris JB, Dixon MG, Nsele PM, Kizito GM, et al. Immunogenicity of fractional-dose vaccine during a yellow fever outbreak—preliminary report. N Engl J Med. 2018. https://doi.org/10.1056/NEJMoa1710430

  12. Soentjens P, Andries P, Aerssens A, Tsoumanis A, Ravinetto R, Heuninckx W, et al. Pre-exposure intradermal rabies vaccination: a non-inferiority trial in healthy adults on shortening the vaccination schedule from 28 to 7 days. Clin Infect Dis. 2018. https://doi.org/10.1093/cid/ciy513

  13. Hampson K, Coudeville L, Lembo T, Sambo M, Kieffer A, Attlan M, et al. Estimating the global burden of endemic canine rabies. PLoS Negl Trop Dis. 2015;9(4):e0003709.

    Article  Google Scholar 

  14. Dodet B, Durrheim DN, Rees H. Rabies: underused vaccines, unnecessary deaths. Vaccine. 2014;32(18):2017–9.

    Article  Google Scholar 

  15. World Health Organization. Zero by 30: the global strategic plan to prevent human deaths from dog-transmitted rabies by 2030. 2017. http://www.who.int/rabies/Executive_summary_draft_V3_wlogo.pdf?ua=1. Accessed 1 July 2018.

  16. Jonker EFF, Visser LG. Single visit rabies pre-exposure priming induces a robust anamnestic antibody response after simulated post-exposure vaccination: results of a dose-finding study. J Travel Med. 2017;24(5).

    Google Scholar 

  17. World Health Organization. Rabies vaccines: WHO position paper—April 2018. Weekly Epidemiological Record No. 16, 2018, 93, 201–20. Weekly Epidemiological Record 2018;93(16):201–20. http://www.who.int/rabies/resources/who_wer9316/en/. Accessed 1 July 2018.

  18. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–7.

    Article  CAS  Google Scholar 

  19. Anderson KB, Endy TP, Thomas SJ. The dynamic role of dengue cross-reactive immunity: changing the approach to defining vaccine safety and efficacy. Lancet Infect Dis. 2018;18(1):333–8.

    Article  Google Scholar 

  20. Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, et al. Antibody-dependent enhancement of severe dengue disease in humans. Science. 2017;358(6365):929–32.

    Article  CAS  Google Scholar 

  21. Dyer O. Philippines halts dengue immunisation campaign owing to safety risk. BMJ. 2017;359:j5759.

    Article  Google Scholar 

  22. Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med. 2018;379:327–40.

    Article  Google Scholar 

  23. Saez-Llorens X, Tricou V, Yu D, Rivera L, Jimeno J, Villarreal AC, et al. Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2–17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study. Lancet Infect Dis. 2018;18(2):162–70.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Rossanese, A. (2019). Travel Vaccination. In: Michel, JP., Maggi, S. (eds) Adult Vaccinations. Practical Issues in Geriatrics. Springer, Cham. https://doi.org/10.1007/978-3-030-05159-4_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-05159-4_17

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-05158-7

  • Online ISBN: 978-3-030-05159-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics